

9853 Pacific Heights Blvd. Suite D. San Diego, CA 92121, USA Tel: 858-263-4982

Email: info@abeomics.com

12-4289: Phospho-c-Cbl (Tyr774) (Clone: R4C5) rabbit mAb

Clonality: Monoclonal **Clone Name:** CblY774-R4C5 Application: FACS.WB Reactivity: Human, Mouse Conjugate: Unconjugated Format: **Purified**

E3 ubiquitin-protein ligase CBL, Casitas B-lineage lymphoma proto-oncogene, Proto-oncogene

Alternative Name: c-Cbl, RING finger protein 55, RING-type E3 ubiquitin transferase, Signal transduction protein

CBL, CBL2, RNF55

Isotype: Rabbit IgG1k

A synthetic phospho-peptide corresponding to residues surrounding Tyr774 of human **Immunogen Information:**

phospho c-Cbl

Description

The c-Cbl (Casitas B-lineage Lymphoma) proto-oncogene is a ubiquitously expressed cytoplasmic adaptor protein that contains multiple functional domains, including an amino-terminal tyrosine kinase-binding (TKB) domain, a RING finger motif, and a proline-rich region. The TKB recognizes phosphorylated tyrosines on activated receptor tyrosine kinases (RTKs) and on other nonreceptor tyrosine kinases, while the RING finger motif recruits ubiquitin-conjugating enzymes. These two domains are primarily responsible for the ubiquitin ligase activity of c-Cbl and downregulation of RTKs (1). The proline-rich region contains 14-3-3 protein-binding and SH3 domain-binding motifs. c-Cbl is phosphorylated at Y700, Y731, and Y774 by Sykand Src-family kinases after the stimulation of some integrins and a wide variety of receptors for immunoglobulins, antigens, hormones, growth factors, and cytokines. Phosphorylated Y774 interacts with the SH2 domain of Crk (1,2). The c-Cbl adapter protein is expressed in the cytoplasm in all tissues, with especially high levels of expression in hematopoietic cells (3,4). Through its many functional sites, c-Cbl plays key roles in the positive and negative regulation of vital cell functions, including T Cell Receptor-mediated cellular immune responses. In human cancer tissues, c-Cbl is frequently tyrosinephosphorylated in a tumor-specific manner (5).

Product Info

 $20 \mu l / 200 \mu l$ Amount:

Content: 1X PBS, 0.02% NaN3, 50% Glycerol, 0.1% BSA

Storage condition: Store at -20°C. Avoid repeated freeze and thaw cycles.

Application Note

 $1\tilde{A} \cap \hat{A} \cup \hat{A} \cup \hat{A} \cap \hat{A} \cup \hat{A} \cap \hat{A} \cup \hat{A} \cup$ See product image legends for additional information. (0.5mg/ml, more than 200 western blots)



9853 Pacific Heights Blvd. Suite D. San Diego, CA 92121, USA Tel: 858-263-4982

Email: info@abeomics.com




Fig-1: Western blot analysis of extracts from Ramos or Jurkat cells, imatinib or pervanadate treated using Phospho-c-Cbl (Tyr774) antibody c-CblY774-R4C5 at 0.1 μ g/mL.




Fig 2 : Flow cytometric analysis of Daudi cells secondary antibody only negative control (blue) or untreated (red) or treated with IFNa + IL-4 + pervanadate (green) using Phospho-c-Cbl (Tyr774) antibody CblY774-R4C5 at $0.01 \mu g/mL$.




Fig-3: Western blot analysis of Jurkat cell extract treated with imatinib or with pervanadate using 0.1 μ g/mL Phospho-c-Cbl (Tyr774) antibody CblY774-R4C5 or Company A antibody at 0.04 μ g/mL (manufacturer's recommended concentration) developed using the same exposure.